“…Mutations in V-raf murine sarcoma viral oncogene homolog B1 (BRAF) occur in approximately 2–4% of patients with NSCLC. 13 , 32 , 33 Among these mutations, missense mutations at codon 600 of BRAF (known as V600 mutations) account for around 40% of all BRAF mutations in NSCLC. These BRAF V600 mutations are classified as class I BRAF mutations, as they lead to increased BRAF kinase activity that is not dependent on BRAF dimerization or activation of RAS.…”